Capsule Summary Slidesets

Share

Program Content

Activities

  • Ivo + Ven in mIDH1 Heme
    Phase Ib/II Study of Ivosidenib Plus Venetoclax With or Without Azacitidine in Patients With IDH1-Mutated Hematologic Malignancies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • ENA Plus AZA in ND AML
    Enasidenib Plus Azacitidine vs Azacitidine Monotherapy in mIDH2 Newly Diagnosed Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • Magrolimab + AZA for MDS/AML
    Phase Ib Study of Magrolimab Plus Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • AMG 330 Phase I Trial
    AMG 330 Bispecific T-Cell Engager in Patients With R/R Acute Myeloid Leukemia: Update of First-in-Human Dose-Escalation Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • QUAZAR AML-001: CC-486
    Phase III QUAZAR AML-001: Further Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • KEYNOTE-204: Pembro vs BV in cHL
    Phase III KEYNOTE-204: Pembrolizumab vs Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2020

    Expires: June 08, 2021

  • ASPEN: Zanubrutinib WM
    ASPEN: Phase III Trial of Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2020

    Expires: June 08, 2021

  • Epcoritamab in R/R B-Cell NHL
    Phase I/II Trial of CD3 x CD20 Bispecific Antibody Epcoritamab (GEN3013) in R/R B-Cell NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

  • CheckMate-744 Nivolumab Plus BV
    CheckMate-744: Nivolumab Plus Brentuximab Vedotin in Younger Patients With R/R Classical Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • Acalabrutinib in Heme
    Acalabrutinib Monotherapy in Hematologic Malignancies: Updated Safety and Efficacy Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • BOSTON: QW Selinexor + Vd
    BOSTON: Phase III Trial of Weekly Selinexor, Bortezomib, and Dexamethasone Vs Twice Weekly Bortezomib and Dexamethasone in Pretreated Patients With Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • DREAMM-6 Belantamab Plus Vd
    DREAMM-6: Belantamab Mafodotin Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • KarMMa: Ide-cel in R/R MM
    Phase II KarMMa: Idecabtagene Vicleucel for R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • EVOLVE: Orva-cel in R/R MM
    EVOLVE: Phase I/II Study of BCMA-Targeted CAR T-Cell Therapy Orvacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • STaMINA Follow-up
    STaMINA Long-term Follow-up: Post–Autologous Hematopoietic Cell Transplantation Strategies for Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2020

    Expires: June 09, 2021

  • S1211: Elo + RVd in MM
    SWOG 1211: Phase I/II Trial of Elotuzumab + RVd vs RVd Alone in Newly Diagnosed, High-Risk Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • BELLINI: Ven Plus Vd
    Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • ENDURANCE: KRd vs VRd in ND MM
    Phase III ENDURANCE: Carfilzomib/Len/Dex vs Bortezomib/Len/Dex in Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2020

    Expires: June 08, 2021

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono